Stéphane Dalle
842 works · 25,449 citations · h-index 70
Top works
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
- Diagnosis and management of nail pigmentations
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- Acral lentiginous melanoma: a clinicoprognostic study of 126 cases
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
- Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
- Squamous cell carcinoma of the nail apparatus: clinicopathological study of 35 cases
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients